Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study validated the differential stripping technique on hairless rat skin and found that the P-08–016 formulation delivered more finasteride to the epidermis and appendages compared to P-10–008.

This paper demonstrates that scalp micropigmentation can effectively conceal scalp and hair deformities with high patient satisfaction, offering a non-surgical alternative cosmetic solution.

Stopping finasteride for male pattern hair loss changes neuroactive steroid levels in the brain and blood.

This study found that male pattern hair loss worsened significantly after stopping finasteride, revealing a "rebound effect" where terminal hair transformed into miniaturized hair over 30 months off the drug.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

Stopping sunscreen use on the forehead led to hair regrowth in a woman with frontal fibrosing alopecia.

Two women had skin reactions from a hair loss treatment and got better after stopping use.

Minoxidil helps some bald men, but most lose hair again when stopping.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

Finasteride may decrease semen quality but not harm sperm production, and stopping the drug can improve semen quality; hyperprolactinemia can cause infertility but is treatable with medication.

Finasteride caused breast enlargement in two men, which improved after stopping the medication.

A woman developed facial hair cysts after using a 3% minoxidil solution for hair loss, which disappeared after stopping the treatment and removing the cysts surgically.

In this report, a rare case of gynecomastia was observed in a 76-year-old man using 0.25% topical finasteride for hair loss, with breast tenderness resolving after stopping treatment but persistent enlargement.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Oral minoxidil may slow male pattern baldness and cause body hair growth, but hair loss can happen after stopping it.

GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

This review discusses female pattern hair loss, the most common cause of hair loss in women, highlighting medical treatments like oral antiandrogens and topical minoxidil but reports no new clinical results.

Finasteride can cause lasting erectile dysfunction, low libido, and depression in some patients.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This review discusses topical minoxidil for hair growth, reporting about one-third of users gain new hair, noting diminished effects after a year and increased hair loss if stopped, but provides no new experimental results.

Finasteride can help with hair loss but may cause mental health issues like depression and anxiety.

This study presents a case where a young male with cryptogenic stroke and patent foramen ovale, using finasteride, experienced symptomatic improvement after PFO closure and discontinuing finasteride, suggesting cardiovascular risks associated with the drug.

This study examined lawsuits in Canada involving 5α-reductase inhibitors, revealing that all cases related to persistent erectile dysfunction as a side effect in men treated for hair loss, but no judgments have been made yet against physicians or pharmaceutical companies.

In this report, researchers documented a rare complication linked to levofloxacin, used as a second-line treatment for tuberculosis, which could include various adverse events during TB therapy.

Hair casts are often mistaken for head lice, scalp pain in hair loss is linked to certain nerve factors, eyelash growth treatment is safe and effective, and nail shedding in children may follow hand-foot-mouth disease.

The abstract reports no new clinical results; it describes finasteride’s mechanism of action in androgenetic alopecia and mentions unpublished trial results by the manufacturer and investigators.

This case report identified a possible adverse effect of low-dose oral minoxidil for female pattern hair loss, as a 74-year-old woman developed significant dry mouth that resolved after stopping the medication and recurred upon rechallenge, suggesting a causal link.